SKY 0515
Alternative Names: SKY-0515Latest Information Update: 15 Jul 2024
At a glance
- Originator Skyhawk Therapeutics
- Class Antiparkinsonians; Small molecules
- Mechanism of Action RNA splicing modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Huntington's disease
Most Recent Events
- 10 Jul 2024 Efficacy and adverse events data from a phase I trial in Huntington’s disease released by Skyhawk Therapeutics
- 10 Jul 2024 Skyhawk Therapeutics plans a phase II trial for Huntington’s disease in early next year
- 16 Nov 2023 Phase-I clinical trials in Huntington's disease (In volunteers) in Aaustralia (PO) (ACTRN12623001161617)